Revolutionising Lymphoedema Treatment: Developing a novel wearable MedTech device

Lymphoedema (LE) is a debilitating and incurable disease that causes excessive swelling, with huge lifelong physical, psychological, and socioeconomic consequences. Lack of access to sustainable and cost-effective treatment results in their medical needs being neglected and disease progression. LymphMotion changes all this by providing LE patients with a more cost-effective and accessible device. It is the world’s first portable, lightweight, compression jacket, that will revolutionise the way lymphoedema is managed.


Catalyst R3

Lead Organisation

University College London




Managing Complaints of Ageing

Share this project

About the project

Lymphoedema is a chronic, debilitating, and incurable disease, caused by damage to the lymphatic system (the “plumbing” of the body), resulting in excessive swelling from fluid build-up to the affected area. This causes huge lifelong physical, psychological, and socioeconomic burdens that significantly lowers the patient’s quality of life. Lymphoedema patients face a lifelong struggle to manage their symptoms.

Current treatment of lymphoedema rely heavily on compression therapy to reduce swelling, delivered by certified therapists, or compression devices at specialised clinics, several times a week. There is a severe lack of resources both in the UK and globally to deliver lymphoedema treatment, despite affecting over 250 million people worldwide. These existing approaches are costly and non-portable; meaning access to effective, affordable, and sustainable treatment is a significant burden for patients. Long waiting lists and overstretched NHS services cause delays in patients receiving the critical treatment they require, and the patients’ needs are often overlooked and neglected, causing disease progression.

The aim of this project – “LymphMotion” is to develop a proof-of-concept prototype of a portable and lightweight compression garment, using a co-creation process with lymphoedema patients. The end goal is to: 1) provide a sustainable, safe, effective, affordable, and convenient at home/away treatment, which 2) alleviates pain and prevent disease progression, and 3) improve quality of life by allowing the patient to self-manage their condition, whenever and wherever they need, giving patients a higher sense of self-autonomy over their disease.


Connect with Innovate UK Business Connect

Join Innovate UK Business Connect's mailing list to receive updates on funding opportunities, events and to access Innovate UK Business Connect's deep expertise. Please check your email to confirm your subscription and select your area(s) of interest.